Fiona Wightman - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Fiona Wightman

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

AIDS (London, England)|March 17, 2017

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 15, 2010

Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeletonPaul U Cameron, Suha Saleh, Georgina Sallmann, et al.

Plos Pathogens|November 14, 2014

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyJulian H Elliott, Fiona Wightman, Ajantha Solomon, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

AIDS (London, England)|March 17, 2017

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 15, 2010

Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeletonPaul U Cameron, Suha Saleh, Georgina Sallmann, et al.

Plos Pathogens|November 14, 2014

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyJulian H Elliott, Fiona Wightman, Ajantha Solomon, et al.

Pageof 3